Rgenix, Inc. is a clinical-stage biopharmaceutical company founded by scientists from The Rockefeller University to discover and develop first-in-class small molecules and biologics against previously undruggable drivers of cancer metastasis, using its proprietary RNA-DRIVEr target-discovery platform. Its programs include ompenaclid (RGX-202), an oral SLC6A8/creatine-transporter inhibitor in Phase 2 for RAS-mutant colorectal cancer, abequolixron (RGX-104), an oral LXR agonist in Phase 1b/2, and RGX-019-MMAE, a MERTK-targeting antibody-drug conjugate. The company changed its corporate name from Rgenix to Inspirna in September 2021 and operates from Long Island City, New York. It is a therapeutics developer with no public API, developer program, or machine-readable interface.
Rgenix is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Drug Discovery.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/rgenix: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: rgenix
name: Rgenix
description: Rgenix, Inc. is a clinical-stage biopharmaceutical company founded by scientists from The Rockefeller University
to discover and develop first-in-class small molecules and biologics against previously undruggable drivers of cancer metastasis,
using its proprietary RNA-DRIVEr target-discovery platform. Its programs include ompenaclid (RGX-202), an oral SLC6A8/creatine-transporter
inhibitor in Phase 2 for RAS-mutant colorectal cancer, abequolixron (RGX-104), an oral LXR agonist in Phase 1b/2, and RGX-019-MMAE,
a MERTK-targeting antibody-drug conjugate. The company changed its corporate name from Rgenix to Inspirna in September 2021
and operates from Long Island City, New York. It is a therapeutics developer with no public API, developer program, or machine-readable
interface.
url: https://raw.githubusercontent.com/api-evangelist/rgenix/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-harvest-source-url: https://forgeglobal.com/rgenix_stock/
x-former-name: Rgenix, Inc.
x-current-name: Inspirna, Inc.
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Drug Discovery
- Clinical Trials
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/rgenix-domain-security.yml
- type: Website
url: https://inspirna.com/
- type: PrivacyPolicy
url: https://inspirna.com/privacy-policy/
- type: TermsOfService
url: https://inspirna.com/terms-of-use/
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Rgenix is a clinical-stage oncology drug developer that renamed itself Inspirna in September 2021; rgenix.com now
301s to an unresponsive www.rgenix.com, and the live corporate site inspirna.com is a WordPress marketing site (company/science/pipeline/patients/careers/news)
with no developer section, no GitHub organization, and a 404 on every contract-discovery path.
evidence:
- url: https://inspirna.com/openapi.json
status: 404
- url: https://inspirna.com/.well-known/agent-card.json
status: 404
- url: https://api.github.com/orgs/inspirna
status: 404
- url: http://rgenix.com/
status: 301
checked: '2026-08-26'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →